{"name":"Vyluma, Inc.","slug":"vyluma-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"NVK-002 Concentration 2","genericName":"NVK-002 Concentration 2","slug":"nvk-002-concentration-2","indication":"Phase 3 for phase_3","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"NVK-002 Concentration 1","genericName":"NVK-002 Concentration 1","slug":"nvk-002-concentration-1","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]}],"pipeline":[{"name":"NVK-002 Concentration 2","genericName":"NVK-002 Concentration 2","slug":"nvk-002-concentration-2","phase":"phase_3","mechanism":"NVK-002 Concentration 2 is a small molecule that targets the molecular target.","indications":["Phase 3 for phase_3"],"catalyst":""},{"name":"NVK-002 Concentration 1","genericName":"NVK-002 Concentration 1","slug":"nvk-002-concentration-1","phase":"phase_3","mechanism":"NVK-002 Concentration 1 is a drug that targets the PD-1 receptor.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxNWV9FQjJEcjBlSUlmeUFhcHVRNTlHYnFXOGJRLVR0cDdKYnAxbVlCM2hQTUUxTlVLVWtRSmlIMHhWOVFrYmk3d3RuUFBlTDkyVW9iQ3Y2amN3VlUxNlZnRVFoaU8ycTlGcDljdGswakhKczVYSy0xNE5JVHBKM1RXV2t5X25mQWpqb3JIaHpBR19EaEZxbWYwNTNMYk15a3ZIYk1mY1l4UVhwNllpeGlsLWpXdFhldkotcUd0T2JRWWVIZ2h1UzMzZ0NVWnM2bm5RSXlNaGJMNm1uZGYxYVpCanV1V0RDalQwOUVKUnR0WUh2ajBVQWtEdUNIMDQ3alBVOXpZanFsNEltV09KTzB6X1hzTmVEZw?oc=5","date":"2025-01-29","type":"pipeline","source":"GlobeNewswire","summary":"Vyluma Announces Acceptance of Drug Application for NVK002 - GlobeNewswire","headline":"Vyluma Announces Acceptance of Drug Application for NVK002","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxPVnh1V3FPcjQzdlh5MThHcWNpVUx3cjd3ZDFmWHBIRzJFaG5Fa3YxVFBrOG51Q1VIX05rRU1WSjdmV1N6cldLZldEZmhtMk50WjkxZXA4TGhjVlpJTWNrS2ozTnpyMkJCZ0xIU1JVaDFwNkJQOXJ3YkJLWlVKcEZVYTc2dHBoaTVEV2NzVFRkcHV3SXFhdVN0cnV4QTc3VHlvQS1GenUtU0prRzk2MVR1a1FVeHZ4Z3lWRXVjRV9jZklqTFM3anRzTEpickRVNXQ0NmhEX0JxRjV0cGlTV1UtMXYyVWJPeTR5WmloZE5VaWZvMHhETXBzNnVUS2Y?oc=5","date":"2024-11-14","type":"pipeline","source":"PR Newswire UK","summary":"Presbyopia Treatment Market Set to Reach New Heights with New Therapies and Advancements by 2034 | DelveInsight - PR Newswire UK","headline":"Presbyopia Treatment Market Set to Reach New Heights with New Therapies and Advancements by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPT25oWEd3WHpHTnlDNlV6aHRjUlZMMS15OW9mYmJQVFBucTcySjNHcDJZUjh3T1FmcUF0UnlJSUd5Y1IyTm84R2hBb0ZrS0FNa19CWHVsZlRpSmFsRDQwNURBXy1USUJHWEpYQzduX0Z5cDZrYXdqM0sxQ016MXRLdWhJc1d6N3R5M1hGMjZWQ1BQX0toVWJpSG94bEdfM2pVRC1ZaUV2R2RYUFlib0xwbDZnN1Z4eHljaEE?oc=5","date":"2023-12-12","type":"regulatory","source":"Ophthalmology Times","summary":"Advancements in ophthalmology: A comprehensive look at the FDA's 2023 approvals - Ophthalmology Times","headline":"Advancements in ophthalmology: A comprehensive look at the FDA's 2023 approvals","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi7AJBVV95cUxQOGZXdFBseXVNX21tS2k1TXFpcTRiNVc0Y2p4UEN0WmF1dldWcG1CLVhKOVQtT1ZzM3M3cGI0U1pjM3NyMG5xUThsR3ZBN1NWcVZQSTQ0Y3lBSjBiYTlkVkgwRjF1Z2JaajFmZnJJSUlaUGF2SDFkemdic0FHX2RyMXNIbVdHVnUxX3dweEl3bnFqUTlTTmU2R2M4N3RvaFlPejk0a1ROam5kOGVDNXk3ajY5dmVPSUg3M1h3Uk5TZnQ4OE0yV3ZrcmF5LUtRUGhrOTVBdGpDRk12YS1ra3NtNU9fd2pJektHd1J6ZHZaWng5b0hya0JaOVd6bWlGQk1hbUVaVUxqaFhqbUZiTjh5djB5dEdWU0c0RHFLSEdxQzVtcVFadHQ1U2Yyck9CTXViS0I4Yk1ETjZaUmpCcGtSU1hxQ09tUTh4WjFvS3o5M0lmUmh6YlRsdW9ULUt3S3djaG9mTE5nRi1OYWpv?oc=5","date":"2023-10-19","type":"trial","source":"prnewswire.com","summary":"Myopia Market to Grow at a Substantial Growth Rate During the Study Period (2019-2032), Predicts DelveInsight | Leading Companies - Nevakar, Vyluma, Bausch & Lomb, Sydnexis, Ocumension, ORA, LENZ Ther","headline":"Myopia Market to Grow at a Substantial Growth Rate During the Study Period (2019-2032), Predicts DelveInsight | Leading ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxOd3V1OXpyT2NDeG82cXRWUE1EcWEyZ0Vzc2Z6QkY0LWw4d1d3ZTY1bkVkSmJnRl9SdmZTREFqX2RjZFh0YThqajcxYUhadVZndk94Q0dBMlljSFJJMmNhR1hSUnJCc28zam52d1pQWFF1QkRqSmZzcU5sQmE2NWlWbjUwQmtDVXBMMzJUNzZMdmEtYUZLYmotRlNVdTl0Tmtna3FfZ0MzaDR5MjZPSURRWTZMVmRYRFd3b3JOa1JwRk9yT2FUcEFUVVBpNV9qdnhRdkhYbU9IUkhhVWFyMGFxNEN5aHV4TXhmTloyMllDakhGVXVvVG1XLXpIbDVKZlRKck9xQ1FGcmF1QUZMUjFZeWJOYmxweEVFNV8yZ2V1WmdmNm4z?oc=5","date":"2023-10-11","type":"pipeline","source":"GlobeNewswire","summary":"Vyluma Announces Positive Results From Second Stage of - GlobeNewswire","headline":"Vyluma Announces Positive Results From Second Stage of","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxNSjZzb2xCMUxoMzBoM1Y2WU5uUm9oY1NUS2VVdUZLZG5MYkhGMC1kQTNPZ3pVOUFxY0x5Nnp4aENsTGpldkdMU3UtUlJIdWY5RmNFQUJrNThSQmlMcnVybTlscVpKWFVoTmhnclZ3aWczMWxtczI3TThlUmRfUW5Tc1ZKeWlYSXlBTXNueHotV3NkendzeXduVGlPTlFIR3Qzd0xCUU9EU29pNkRZZmpFZXJxV05TcTBBUmk5cHF6ZDdrUEE3bnFlRGk0aWVtOVpsVkZmWXVCSV9HQ2NwN3JKLWF3blE0U0pTaVpfWUhBNjNtU1drTUE1OWh2bzQ2V2NDNUtnWU1XMDVOcV9sU1VnT0Q4OXhpLUdXT3c?oc=5","date":"2022-10-27","type":"trial","source":"GlobeNewswire","summary":"Vyluma Announces Positive Results From Phase III CHAMP - GlobeNewswire","headline":"Vyluma Announces Positive Results From Phase III CHAMP","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQNzVFOGd6VWFjS29iUlo3MHI0cWFGM3lpd3JwcXh0dzJPeGYtLTRkWEtybU81OVBTd3MwcG9jNDItNEZhLUlySUVVSnpyczItZTlLR2RhUERjS1VxQjJyazV0RWFTbjI0b3ZXY0VvYk9ZWmVkWEwxcUxDd1pwRTZPN3N4Ym4yVFRKaUoyMg?oc=5","date":"2021-06-01","type":"pipeline","source":"Optometry Times","summary":"Nevakar spins off ophthalmic-only company Vyluma - Optometry Times","headline":"Nevakar spins off ophthalmic-only company Vyluma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNTVpYQVlUVkQtNFNZbHVSRDEwRzEyRjZ5MTRrbG1CblFQYTJUb2lwanplMGhFNmlBQ3VVYXJIS3FDNlhKZllvclRkUHVSQkFjTWJsclU2NVJFcGxvMTBLMmY2U0tXZlRNejA5NkxzVlRDRU56WWVOd2E1ZktSX0lna1BuY3pQMUc2Y3Btck1rY1E?oc=5","date":"2021-05-25","type":"pipeline","source":"Ophthalmology Times Europe","summary":"Nevakar unveils ophthalmic subsidiary, Vyluma - Ophthalmology Times Europe","headline":"Nevakar unveils ophthalmic subsidiary, Vyluma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOTFZZY0lXTHBlV3dwbDVlWWJjRFZ2cktQelZPNDJOWWhlaXpUSnRGend4WVJYZi0yV1Z3Zld2a0p1cEFIZl9tMHZ1eGpfQjdiSTM3MHdibjhPb0RKOW5kUVpuVXJmRTdfZDctZUdRT1o0TW1XRWQwby03bTBRLXBST0RQY29jRFZGX3dDdlVJUXNHUUwxZ2pNR3NEdldZR0ppb254cnJja3hEMnI2bzJjQ0lB?oc=5","date":"2021-05-25","type":"pipeline","source":"prnewswire.com","summary":"Nevakar Announces Formation Of Ophthalmic Company, Vyluma - prnewswire.com","headline":"Nevakar Announces Formation Of Ophthalmic Company, Vyluma","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}